An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
At SGO 2022, Catherine Watson, MD, spoke about the 2 arms of a randomized education trial presented at the conference.
In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.
At SGO 2022, Catherine Watson, MD, spoke about how to improve genetic education for patients with ovarian cancer.
Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.
Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.
At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.
In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.